Mutations in interferon sensitivity-determining region of hepatitis C virus: Its relation to change in viral load

American Journal of Gastroenterology

Volumn 95, Issue 7, 2000, Pages 1781-1787

  Terazawa, Yasuyuki ^a   Yoshioka, Kentaro ^a   Kobayashi, Makoto ^a   Watanabe, Kazumasa ^a   Ishigami, Masatoshi ^a   Yano, Motoyoshi ^a   Takagi, Kenji ^a   Kakumu, Shinichi ^b  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION;

ADULT; AMINO ACID SEQUENCE; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; VIRAL LOAD;

EID: 0033915007     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)00968-0     Document Type: Article

References (31)

1. Choo Q.-L., Kuo G., Weiner A.J., et al. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362.
2. Kuo G., Choo Q.-L., Alter H.J., et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 244:1989;362-364.
3. Alter M.J., Margolis H.S., Krawczynski K., et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med. 327:1992;1899-1905.
4. Tong M.J., El-Farra N.S., Reikes A.R., et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 332:1995;1463-1466.
5. Kiyosawa K., Sodeyama T., Tanaka E., et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma Analysis by detection of antibody to hepatitis C virus . Hepatology. 12:1990;671-675.
6. Davis G.L., Balart L.A., Schiff E.R., et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med. 321:1989;1501-1506.
7. Di Bisceglie A.M., Martin P., Kassianides C., et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
8. Marcellin P., Boyer N., Giostra E., et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis A multicenter randomized controlled trial from France . Hepatology. 13:1991;393-397.
9. Enomoto N., Sakuma I., Asahina Y., et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest. 96:1995;224-230.
10. Enomoto N., Sakuma I., Asahina Y., et al. Mutations in the nonstructural protein 5A gene and response to interferon in the patients with chronic hepatitis C virus 1b infection. N Engl J Med. 334:1996;77-81.
11. Kurosaki M., Enomoto N., Murakami T., et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-β therapy. Hepatology. 25:1997;750-753.
12. Kato N., Hijikata M., Ootsuyama Y., et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA. 87:1990;9524-9528.
13. Chayama K., Tsubota A., Kobayashi M., et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology. 25:1997;745-749.
14. Sáiz J.-C., López-Labrador F.-Z., Ampurdanés S., et al. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J Infect Dis. 177:1998;839-847.
15. Zeuzem S., Lee J.-H., Roth W.K. Mutations in nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology. 25:1997;740-744.
16. Khorsi H., Castelain S., Wyseur A., et al. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol. 27:1997;72-77.
17. Squadrito G., Leone F., Sartori M., et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C virus to interferon alfa. Gastroenterology. 113:1997;567-572.
18. Polyak S.J., McArdle S., Liu S.-L., et al. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol. 72:1998;4288-4296.
19. Hollingsworth R.C., Sillekens P., van Deursen P., et al. Serum HCV RNA levels assessed by quantitative NASBA® Stability of viral load over time, and lack of correlation with liver disease . J Hepatol. 25:1996;301-306.
20. Nguyen T.T., Sedghi-Vaziri A., Wilkes L.B., et al. Fluctuations of viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat. 3:1996;75-78.
21. Yoshioka K., Aiyama T., Iwata K., et al. Serial quantitation of serum core protein and viral RNA of hepatitis C virus after interferon therapy Increase in viral loads in biochemical responders . Am J Gastroenterol. 92:1997;1305-1309.
22. Okamoto H., Sugiyama Y., Okada S., et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers Application to clinical surveys and tracing infectious sources . J Gen Virol. 73:1992;673-679.
23. Simmonds P., McOmish F., Yap P.L., et al. Sequence variability in the 5′ non-coding region of hepatitis C virus Identification of a new virus type and restrictions on sequence diversity . J Gen Virol. 74:1993;661-668.
24. Desmet V.J., Gerber M., Hoofnagle J.H., et al. Classification of chronic hepatitis Diagnosis, grading and staging . Hepatology. 19:1994;1513-1520.
25. Meurs E., Chong K.L., Galabru J., et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell. 62:1990;379-390.
26. Gale M. Jr, Korth M.J., Tang N.M., et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 230:1997;217-227.
27. Gale M. Jr, Blakely C.M., Kwieciszewski B., et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein Molecular mechanisms of kinase regulation . Mol Cell Biol. 18:1998;5208-5218.
28. Polyak S.J., Paschal D.M., McArdle S., et al. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology. 29:1999;1262-1271.
29. Song J., Fujii M., Wang F., et al. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. J Gen Virol. 80:1999;879-886.
30. Gale M. Jr, Kwieciszewski B., Dossett M., et al. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol. 73:1999;6506-6516.
31. Paterson M., Laxton C.D., Thomas H.C., et al. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology. 117:1999;1187-1197.